GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: A systematic meta-analysis

Molecular Neurobiology

Volumn 48, Issue 3, 2013, Pages 404-411

  Tang, Hui ^a,c   Shen, Na ^b   Jin, Huijuan ^a   Liu, Dan ^a,d   Miao, Xiaoping ^b   Zhu, Ling Qiang ^a,d  

^a Basic Medical School   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bipolar disorder; GSK 3; Meta analysis; Schizophrenia

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ALLELE; BIPOLAR DISORDER; DISEASE COURSE; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; MUTANT; PROMOTER REGION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

BIPOLAR DISORDER; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84888002407     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8414-x     Document Type: Review

References (54)

1. Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276(40):37436-37442
2. Hoshi M, Takashima A, Noguchi K et al (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA 93(7):2719-2723
3. Perez-Costas E, Gandy JC, Melendez-Ferro M et al (2010) Light and electron microscopy study of glycogen synthase kinase-3beta in the mouse brain. PLoS One 5(1):e8911
4. Adachi A, Kano F, Tsuboi T et al (2010) Golgi-associated GSK3beta regulates the sorting process of post-Golgi membrane trafficking. J Cell Sci 123(Pt 19):3215-3225
5. Bijur GN, Jope RS (2003) Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 14(18):2415-2419
6. Mukai F, Ishiguro K, Sano Y et al (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81(5):1073-1083
7. Wexler EM, Geschwind DH (2011) DISC1: a schizophrenia gene with multiple personalities. Neuron 72(4):501-503
8. Jope RS (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4(2):117-128
9. Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41:789-813
10. Detera-Wadleigh SD (2001) Lithium-related genetics of bipolar disorder. Ann Med 33(4):272-285
11. Gould TD, Manji HK (2002) The Wnt signaling pathway in bipolar disorder. Neuroscientist 8(5):497-511
12. Manji HK, Moore GJ, Chen G (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46(7):929-940
13. Valvezan AJ, Klein PS (2012) GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front Mol Neurosci 5:1
14. Kozlovsky N, Belmaker RH, Agam G (2002) GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 12(1):13-25
15. Kozlovsky N, Nadri C, Agam G (2005) Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 15(1):1-11
16. Lovestone S, Killick R, Di Forti M et al (2007) Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30(4):142-149
17. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44(7):660-669
18. Kozlovsky N, Belmaker RH, Agam G (2000) Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157(5):831-833
19. Benedetti F, Bernasconi A, Lorenzi C et al (2004) A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 355(1-2):37-40
20. Lin YF, Huang MC, Liu HC (2012) Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord. doi: 10.1016/j.jad.2012.08.025
21. Benedetti F, Poletti S, Radaelli D et al (2010) Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity. Gene Brain Behav 9(4):365-371
22. Scassellati C, Rotondo A, Bonvicini C et al (2007) Further evidence on the lack of association between glycogen synthase kinase 3beta gene polymorphisms and bipolar disorder. Psychiatr Genet 17(4):249-250
23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558
24. Harris RJ, Bradburn MJ, Deeks JJ et al (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8(1):3-28
25. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101
26. Egger M, Davey SG, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
27. Nishiguchi N, Breen G, Russ C et al (2006) Association analysis of the glycogen synthase kinase-3beta gene in bipolar disorder. Neurosci Lett 394(3):243-245
28. Szczepankiewicz A, Skibinska M, Slopien A et al (2005) Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology 53(1):51-6
29. Ikeda M, Iwata N, Suzuki T et al (2005) No association of GSK3beta gene (GSK3B) with Japanese schizophrenia. Am J Med Genet B Neuropsychiatr Genet 134B(1):90-92
30. Kim T, Song J, Shin Y et al (2004) Association of a polymorphism of glycogen synthase kinase-3 beta (GSK-3 beta) gene and schizophrenia in Korean population. Int J Neuropsychopharmacol 7:S430-S430
31. Kim YH, Lee JG, Lee SJ (2006) Association study of the glycogen synthase kinase-3 beta (GSK-3 beta)-50T/C polymorphism with schizophrenia; association with depression and cognitive impairment. Eur Neuropsychopharmacol 16:S447-S447
32. Meng J, Shi Y, Zhao X et al (2008) No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese population. J Psychiatr Res 42(5):365-370
33. Skibinska M, Kapelski P, Hauser J (2011) Family-based association study of glycogen synthase kinase 3 (GSK3)-beta gene polymorphism in schizophrenia. Eur Neuropsychopharmacol 21:S143-S144
34. Lee KY, Ahn YM, Joo EJ et al (2006) No association of two common SNPs at position -1727 A/T, -50 C/T of GSK-3 beta polymorphisms with schizophrenia and bipolar disorder of Korean population. Neurosci Lett 395(2):175-178
35. Szczepankiewicz A, Skibinska M, Hauser J et al (2006) Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology 53(1):51-56
36. Li M, Mo Y, Luo XJ et al (2011) Genetic association and identification of a functional SNP at GSK3beta for schizophrenia susceptibility. Schizophr Res 133(1-3):165-171
37. Souza RP, Romano-Silva MA, Lieberman JA et al (2008) Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 200(2):177-186
38. Souza RP, Remington G, Chowdhury NI et al (2010) Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol 20(10):688-694
39. Hosgood HR, Menashe I, Shen M et al (2008) Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 29(10):1938-1943
40. Goodarzi MO, Antoine HJ, Pall M et al (2007) Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. Fertil Steril 87(6):1473-1476
41. Brunet-Gouet E, Decety J (2006) Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res 148(2-3):75-92
42. Picchioni MM, Murray RM (2007) Schizophrenia. BMJ 335(7610):91-95
43. Mcglashan TH, Fenton WS (1991) Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 17(4):609-632
44. van Os J, Kapur S (2009) Schizophrenia. Lancet 374(9690):635-645
45. Lymer GK, Job DE, William T et al (2006) Brain-behaviour relationships in people at high genetic risk of schizophrenia. NeuroImage 33(1):275-285
46. Kircher TT, Thienel R (2005) Functional brain imaging of symptoms and cognition in schizophrenia. Prog Brain Res 150:299-308
47. Ross CA, Margolis RL, Reading SA et al (2006) Neurobiology of schizophrenia. Neuron 52(1):139-153
48. Rapoport JL, Addington AM, Frangou S et al (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10(5):434-449
49. Mao Y, Ge X, Frank CL et al (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136(6):1017-1031
50. Kieseppa T, Partonen T, Haukka J et al (2004) High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 161(10):1814-1821
51. Badenhop RF, Moses MJ, Scimone A et al (2002) A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19. Mol Psychiatry 7(6):594-603
52. Bailer U, Leisch F, Meszaros K et al (2002) Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry 52(1):40-52
53. Benedetti F, Bollettini I, Barberi I et al (2013) Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology 38(2):313-327
54. Inkster B, Nichols TE, Saemann PG et al (2009) Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 66(7):721-728